We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+22.47%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$56.9M
Cap. Flow
+$26.1M
Cap. Flow %
7.19%
Top 10 Hldgs %
84.78%
Holding
30
New
4
Increased
7
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
AKAO
Achaogen Inc
AKAO
+$12.6M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$9.41M
3
XLRN
Acceleron Pharma
XLRN
+$8.99M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$7.98M
5
ASND icon
Ascendis Pharma A/S
ASND
+$7.54M

Top Sells

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$8.07M
2
FBRX icon
Forte Biosciences
FBRX
+$5.46M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.29M
4
LOXO
Loxo Oncology, Inc
LOXO
+$4.86M
5
DERM
Dermira, Inc.
DERM
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 49.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$94.8M 26.11%
1,950,477
– –
ALDR
2
DELISTED
Alder Biopharmaceuticals
ALDR
$36M 9.93%
2,942,203
+765,000
+35% +$7.98M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$33.3M 9.16%
2,379,367
+438,517
+23% +$4.37M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$32.6M 8.97%
467,682
+7,682
+2% +$411K
AKAO
5
DELISTED
Achaogen Inc
AKAO
$30.5M 8.4%
1,912,106
+662,106
+53% +$12.6M
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
$22.6M 6.23%
912,001
– –
WVE icon
7
Wave Life Sciences
WVE
$1.13B
$18.8M 5.17%
863,327
-140,773
-14% -$2.83M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$16.2M 4.46%
849,693
+50,330
+6% +$768K
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$12.6M 3.48%
+295,000
New +$9.41M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$10.4M 2.87%
278,753
+258,867
+1,302% +$8.99M
ASND icon
11
Ascendis Pharma A/S
ASND
$16.3B
$10.3M 2.85%
285,143
+262,743
+1,173% +$7.54M
VRNA
12
DELISTED
Verona Pharma
VRNA
$9.35M 2.57%
608,851
-4,750
-0.8% -$62.7K
ACRS icon
13
Aclaris Therapeutics
ACRS
$733M
$6.79M 1.87%
+262,950
New +$7.05M
PACB icon
14
Pacific Biosciences
PACB
$426M
$6.04M 1.66%
1,150,000
-100,000
-8% -$430K
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$4.84M 1.33%
+600,000
New +$4.06M
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
$4.61M 1.27%
50,000
-62,500
-56% -$4.86M
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.3B
$4.5M 1.24%
+100,000
New +$1.87M
ARGX icon
18
argenx
ARGX
$54.8B
$3.99M 1.1%
176,500
– –
FBRX icon
19
Forte Biosciences
FBRX
$1.57B
$3.65M 1.01%
782
-1,226
-61% -$5.46M
DERM
20
DELISTED
Dermira, Inc.
DERM
$1.16M 0.32%
43,071
-133,140
-76% -$3.48M
ABEO icon
21
Abeona Therapeutics
ABEO
$340M
– –
-733
Closed -$117K
ARDX icon
22
Ardelyx
ARDX
$1.25B
– –
-37,500
Closed -$191K
KYNB
23
Kyntra Bio
KYNB
$29M
– –
-10,000
Closed -$8.07M
LRMR icon
24
Larimar Therapeutics
LRMR
$393M
– –
-19,508
Closed -$822K
SGMO
25
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-154,000
Closed -$1.35M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2017 Portfolio in Review

As of Q3 2017, Foresite Capital Management III held 30 positions worth $363M, up 19% from $306M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Foresite Capital Management III deployed $26.1M of net new capital in Q3 2017, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 295,000 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 44% a quarter earlier.

On the sell side, the largest reduction was Forte Biosciences, an estimated $5.46M trimmed.

  • Foresite Capital Management III's largest Q3 2017 buy was MyoKardia, Inc. Common Stock: 295,000 shares worth $12.6M.
  • Foresite Capital Management III added most to Achaogen Inc in Q3 2017, an estimated $12.6M increase.
  • Foresite Capital Management III's biggest Q3 2017 reduction was Forte Biosciences, cutting an estimated $5.46M.
  • Foresite Capital Management III fully exited Kyntra Bio in Q3 2017, selling an estimated $8.07M.
  • Foresite Capital Management III's ten largest holdings make up 85% of its $363M portfolio in Q3 2017.
  • Foresite Capital Management III opened 4 new positions and closed 10 in Q3 2017.
  • Foresite Capital Management III's portfolio value rose 19% quarter-over-quarter to $363M.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.